WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2005032560) BIOLOGICAL ACTION OF OPTICALLY ACTIVE ISOMERS OF DIGOXIN
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2005/032560    International Application No.:    PCT/US2004/031772
Publication Date: 14.04.2005 International Filing Date: 29.09.2004
IPC:
A61K 31/70 (2006.01), C07J 1/00 (2006.01)
Applicants: SOMBERG, John, Charin [US/US]; (US).
RANADE, Vasant, V. [IN/US]; (US)
Inventors: SOMBERG, John, Charin; (US).
RANADE, Vasant, V.; (US)
Agent: FATO, Gildo, E.; Law Office of Laurence M. Dunlap, Ltd., 14047 Petronella Drive, Suite 202B, Libertyville, IL 60048 (US)
Priority Data:
60/506,859 30.09.2003 US
Title (EN) BIOLOGICAL ACTION OF OPTICALLY ACTIVE ISOMERS OF DIGOXIN
(FR) SEPARATION CHIRALE, CARACTERISATION ET ACTION BIOLOGIQUE D'ISOMERES DE DIGOXINE OPTIQUEMENT ACTIFS
Abstract: front page image
(EN)Disclosed herein is the method for separation of enantiomers or isomers of digoxin. These isomers are to be used in the treatment of heart failure without adverse or unneeded cardiac actions in humans. Additionally what is claimed is an isolate with less or no cardiac contractile effect but with AV node slowing such that the composition would be an effective therapy for the control of the ventricular response in atrial fibrillation. Also disclosed are methods for assaying these isomeric compounds present in biological fluids to enable the separation of pharmacologic actions.
(FR)L'invention concerne un procédé de séparation d'énantiomères ou d'isomères de digoxine. Ces isomères doivent être utilisés dans le traitement d'insuffisance cardiaque sans conséquences ni actions cardiaques inutiles chez les humains. En outre, l'invention concerne un isolat avec ou sans effet contractile cardiaque, mais avec un ralentissement de la conduction AV, la composition pouvant donc constituer une thérapie efficace par maîtriser la réponse ventriculaire en fibrillation atriale. L'invention concerne également des procédés de dosage de ces composés isomères présents dans des liquides biologiques pour permettre la séparation des actions pharmacologiques.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)